SCHEMBL27181592

SCHEMBL27181592

O=C(Nc1cccc(S(=O)(=O)Nc2cccc(Cl)c2)c1)c1ccc(Br)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.53
▸ KMT2A Q03164 7/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ MAPT P10636 3/20 0.53
▸ HTT P42858 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ ESR1 P03372 3/20 0.51
▸ ESRRG P62508 3/20 0.51
▸ ESR2 Q92731 2/20 0.51
▸ LMNA P02545 2/20 0.51
▸ PTBP1 P26599 1/20 0.51
▸ GPR27 Q9NS67 1/20 0.51
▸ HPGD P15428 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ PGR P06401 2/20 0.49
▸ TSHR P16473 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31337210 0.87 ESR1 (0.64) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL30926458 0.76 GRM4 (0.74) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL27181366 0.76 GRM4 (0.74) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL27180905 0.73 MAPT (0.65) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL27180383 0.72 ALDH1A1 (0.66) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL30926474 0.72 ALDH1A1 (0.66) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL27180778 0.72 MAPK1 (0.62) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL30926756 0.72 MEN1 (0.55) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL27180901 0.72 MEN1 (0.55) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL23412434 0.72 MEN1 (0.68) MEN1KMT2ASMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580404-A2 SULFONAMIDE APYRASE INHIBITORS Texas Crop Science, Inc. (US) 2025-07-09 — — EP claimed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 — — US claimed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 — — WO claimed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 — — US disclosed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS APEH, ARSA, DNPEP MEN1 4795/4885KMT2A 2544/4885SMN1; SMN2 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback